ATM Sales Drive Series B Warrant Price Down to $1.22 for Sunshine Biopharma
SBFM is trading near its 52-week low of $1.1 (9.1% above the low) on light trading volume (0.1× avg).
Summary
Sunshine Biopharma disclosed that its Series B Warrant exercise price has been reduced to $1.2202 due to recent sales under its $4 million at-the-market equity program, increasing potential dilution.
Key Events · Financing and Capital Events · SBFM
-
Series B Warrant Price Cut
The exercise price has been reduced to $1.2202 from a prior higher level due to recent ATM sales, increasing potential dilution for existing shareholders.
-
ATM Program Active
The $4 million at-the-market facility established July 20, 2026 is being utilized, triggering the warrant price adjustment.
-
Financial Distress Context
This follows a 1-for-10 reverse split, a $6 million dilutive offering, and a $1.06 million legal settlement, highlighting the company's urgent need for capital.
-
Potential Further Adjustments
The Series B Warrants are subject to further price reductions based on future equity sales, creating ongoing dilution risk.
Analysis · SBFM · Life Sciences
Active use of the company's at-the-market equity facility has pushed the Series B Warrant exercise price down to $1.2202. This adjustment is a direct result of the $4 million ATM program launched in July 2026. While the ATM itself was previously disclosed, the price cut represents a new material development—it raises the potential dilution from these warrants and confirms that the company is tapping the facility, which could add further pressure on the stock. The move comes against a backdrop of severe financial distress, including a recent reverse split, a dilutive $6 million offering, and a legal settlement.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1666 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SBFM was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $1.10 to $24.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.